Single nucleotide polymorphism MTHFR677C>T and the severity of metabolic side effects of antipsychotics in patients with schizophrenia: the results of a pilot study
https://doi.org/10.31363/2313-7053-2018-3-40-46
Abstract
To predict the development of side effects and personalized selection of drug therapy, it seems relevant to study the association of individual genetic risk factors with undesirable side effects of antipsychotics in chronic patients with schizophrenia. Thereby the purpose of this study was to evaluate the association between the carriage of the T-allele of the single nucleotide genetic polymorphism MTHFR677C>T and the severity of the metabolic side effects of antipsychotics. As a result of the study a greater risk of developing components of the metabolic syndrome was revealed, as well as a significantly higher fasting blood glucose level in the group of carriers of the minor T-allele of polymorphism MTHFR677C>T.
About the Authors
M. A. Kosataya
«Privolzhskiy Research Medical University», Nizhny Novgorod
Russian Federation
Russian Federation
A. V. Marina
«Privolzhskiy Research Medical University», Nizhny Novgorod
Russian Federation
Russian Federation
A. V. Sergeeva
«Privolzhskiy Research Medical University», Nizhny Novgorod
Russian Federation
Russian Federation
T. V. Zhilyaeva
«Privolzhskiy Research Medical University», Nizhny Novgorod
Russian Federation
Russian Federation
A. S. Blagonravova
«Privolzhskiy Research Medical University», Nizhny Novgorod
Russian Federation
Russian Federation
G. E. Mazo
«National Medical Research Center for Psychiatry and Neurology named after V.M. Bekhterev», Saint-Petersburg
Russian Federation
Russian Federation
References
1. Volkov, V.P. Natural causes of death of patients with schizophrenia // Psihicheskoe zdorove. — 2013. — T. 11. — №. 12. — S. 52-57. (In Rus.).
2. Kibitov, A.O., Ivaschenko, D.V., Syichev, D.A. Pharmacogenetic approach to increase efficacy and safety of schizophrenia treatment with antipsychotics // Sovremennaya terapiya psihicheskih rasstroystv. — 2017. — №. 1. — S. 2-13. (In Rus.). DOI:10.21265/PSYPH.2017.40.4982.
3. Kibitov, A.O., Mazo, G.E. Metabolic side effects of atypical antipsychotics: interindividual variability and genetic risk. Sotsialnaya i klinicheskaya psihiatriya. — 2018. — T. 28. — № 1. -S. 78-88. (In Rus.).
4. Mazo, G.E. Prospects for development of endocrinological psychiatry / Sbornik nauchnyih trudov «Sovremennyie dostizheniya v diagnostike i lechenii endogennyih psihicheskih rasstroystv». — S.-Pb., 2008. — S. 210 — 224. (In Rus.).
5. Neznanov, N.G. Kozlova S.N., Mazo G.E., Shlyakhto N.G., Smirnov B.I. Comorbidity of depressive disorders and coronary heart disease: general aspects of pathogenesis // Zhurnal nevrologii i psihiatrii im Korsakova. 2015. № 5. S. 20 — 26. (In Rus.). DOI:10.17116/jnevro20151155120-26
6. Boldyrev, A.A. Molecular mechanisms of homocysteine toxicity. Biochemistry (Moscow). — 2009. — Vol. 74. — № 6. — P. 589–598. doi:10.1134/s0006297909060017
7. Devlin, A. M., Ngai, Y. F., Ronsley, R., Panagiotopoulos, C. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Translational Psychiatry. — 2012. — Vol. 2. — №1. — P. e71–e71. doi:10.1038/tp.2011.68
8. Kao, A. C. C., Rojnic Kuzman, M., Tiwari, A. K. et al. Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. Journal of Psychiatric Research. — 2014. — Vol. 54. — P. 36–42. doi:10.1016/j.jpsychires.2014.03.012
9. Klerk, M., Verhoef, P., Clarke, R. et al. MTHFR 677C–>T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. — 2002. — Vol. 288. — № 16. — P. 2023–2031. doi:10.1001/jama.288.16.2023
10. Kugathasan, P., Jensen, S. E., Laursen, T. M., Aagaard, J., Nielsen, R. E. P6497Increased mortality following myocardial infarction in patients with schizophrenia: a national population based cohort study. European Heart Journal. — 2017. — Vol. 38(suppl_1). doi:10.1093/eurheartj/ehx493.p6497
11. Li, Y., Huang, T., Zheng, Y. et al. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. — 2016. — Vol. 5. — № 8. — P. e003768. doi:10.1161/jaha.116.003768
12. Liew, S.-C., Gupta, E. D. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases. European Journal of Medical Genetics. — 2015. — Vol. 58. — № 1. — P. 1–10. doi:10.1016/j.ejmg.2014.10.004
13. Lind, M. V., Lauritzen, L., Vestergaard, H. et al. One-carbon metabolism markers are associated with cardiometabolic risk factors. Nutrition, Metabolism and Cardiovascular Diseases. — 2018.- Vol. 28. — № 4. — P. 402–410. doi:10.1016/j.numecd.2018.01.005
14. Liu, J., Jia, X., Li, H. et al. Association between MTHFR C677T polymorphism and abdominal aortic aneurysm risk. Medicine. — 2016. — Vol. 95. — № 36. — P. e4793. doi:10.1097/md.0000000000004793
15. MacNeil, R.R., Müller, D.J. Genetics of Common Antipsychotic-Induced Adverse Effects. Molecular Neuropsychiatry. — 2016. — Vol. 2. — № 2. — P. 61–78. doi:10.1159/000445802
16. Misiak, B., Łaczmański, Ł., Słoka, N. K. et al. Genetic Variation in One-Carbon Metabolism and Changes in Metabolic Parameters in First-Episode Schizophrenia Patients. International Journal of Neuropsychopharmacology. — 2016. — pyw094. doi:10.1093/ijnp/pyw094
17. Roffman, J. L., Weiss, A. P., Purcell, S. et al. Contribution of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms to Negative Symptoms in Schizophrenia. Biological Psychiatry. — 2008. — Vol. 63. — № 1. — P. 42–48. doi:10.1016/j.biopsych.2006.12.017
18. Van Winkel, R., Moons, T., Peerbooms, O. et al. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. International Clinical Psychopharmacology. — 2010. — Vol. 25. — № 5. — P. 270–276. doi:10.1097/yic.0b013e32833bc60d
19. Yeh, J.-K., Chen, C.-C., Hsieh, M.-J. et al. Impact of Homocysteine Level on Long-term Cardiovascular Outcomes in Patients after Coronary Artery Stenting. Journal of Atherosclerosis and Thrombosis. — 2017. — Vol. 24. — №7. — P. 696–705. doi:10.5551/jat.36434
Review
For citations:
Kosataya M.A., Marina A.V., Sergeeva A.V., Zhilyaeva T.V., Blagonravova A.S., Mazo G.E. Single nucleotide polymorphism MTHFR677C>T and the severity of metabolic side effects of antipsychotics in patients with schizophrenia: the results of a pilot study. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2018;(3):40-46. (In Russ.) https://doi.org/10.31363/2313-7053-2018-3-40-46
Views:
734
Email this article 